AMARIN CORPORATION PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.91 USD | -0.87% |
|
+4.01% | +4.60% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company shows low valuation levels, with an enterprise value at 0.26 times its sales.
- The company's share price in relation to its net book value makes it look relatively cheap.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Most analysts recommend that the stock should be sold or reduced.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +4.60% | 374M | C | ||
| -1.43% | 104B | B+ | ||
| +8.96% | 105B | B+ | ||
| +4.40% | 22.94B | B | ||
| -12.15% | 22.34B | B+ | ||
| -4.36% | 19.25B | A- | ||
| -39.98% | 17.08B | A- | ||
| -10.04% | 16.96B | B | ||
| +6.79% | 14.16B | C+ | ||
| +38.61% | 12.63B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- AMRN Stock
- Ratings Amarin Corporation plc
